Broad neutralization of SARS-related viruses by human monoclonal antibodies.

Saved in:

Bibliographic Details
Title:	Broad neutralization of SARS-related viruses by human monoclonal antibodies.
Authors:	Wec, Anna Z., Wrapp, Daniel, Herbert, Andrew S., Maurer, Daniel P., Haslwanter, Denise, Sakharkar, Mrunal, Jangra, Rohit K., Dieterle, M. Eugenia, Lilov, Asparouh, Huang, Deli, Tse, Longping V., Johnson, Nicole V., Hsieh, Ching-Lin, Wang, Nianshuang, Nett, Juergen H., Champney, Elizabeth, Burnina, Irina, Brown, Michael, Lin, Shu, Sinclair, Melanie
Source:	Science (pre-March 2025). 8/7/2020, Vol. 369 Issue 6504, p731-736. 6p. 4 Diagrams.
Subjects:	Coronaviruses, B cells, SARS disease, Immunoglobulins, Somatic mutation
Abstract:	Broadly protective vaccines against known and preemergent human coronaviruses (HCoVs) are urgently needed. To gain a deeper understanding of cross-neutralizing antibody responses, we mined the memory B cell repertoire of a convalescent severe acute respiratory syndrome (SARS) donor and identified 200 SARS coronavirus 2 (SARS-CoV-2) binding antibodies that target multiple conserved sites on the spike (S) protein. A large proportion of the non-neutralizing antibodies display high levels of somatic hypermutation and cross-react with circulating HCoVs, suggesting recall of preexisting memory B cells elicited by prior HCoV infections. Several antibodies potently cross-neutralize SARS-CoV, SARS-CoV-2, and the bat SARS-like virus WIV1 by blocking receptor attachment and inducing S1 shedding. These antibodies represent promising candidates for therapeutic intervention and reveal a target for the rational design of pan-sarbecovirus vaccines. [ABSTRACT FROM AUTHOR]
	Copyright of Science (pre-March 2025) is the property of American Association for the Advancement of Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	Psychology and Behavioral Sciences Collection

Description
Abstract:	Broadly protective vaccines against known and preemergent human coronaviruses (HCoVs) are urgently needed. To gain a deeper understanding of cross-neutralizing antibody responses, we mined the memory B cell repertoire of a convalescent severe acute respiratory syndrome (SARS) donor and identified 200 SARS coronavirus 2 (SARS-CoV-2) binding antibodies that target multiple conserved sites on the spike (S) protein. A large proportion of the non-neutralizing antibodies display high levels of somatic hypermutation and cross-react with circulating HCoVs, suggesting recall of preexisting memory B cells elicited by prior HCoV infections. Several antibodies potently cross-neutralize SARS-CoV, SARS-CoV-2, and the bat SARS-like virus WIV1 by blocking receptor attachment and inducing S1 shedding. These antibodies represent promising candidates for therapeutic intervention and reveal a target for the rational design of pan-sarbecovirus vaccines. [ABSTRACT FROM AUTHOR]
ISSN:	00368075
DOI:	10.1126/science.abc7424